3.88
3.88 (0%)
As of Feb 14, 2025
Lipella Pharmaceuticals Inc [LIPO]
Source:
Company Overview
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology companythat was incorporated under the laws of the State of Delaware in February 2005. We are focused on developing new drugs by reformulatingthe active agents in existing generic drugs and optimizing these reformulations for new applications.
| Country | United States |
| Headquarters | pittsburgh, pennsylvania |
| Phone Number | (412) 901-0315 |
| Industry | manufacturing |
| CEO | Jonathan Kaufman |
| Website | lipella.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0.5 |
| Operating Profit | $-5.1 |
| Net Income | $-5 |
| Net Cash | $-1.1 |
Profit Ratios
| Gross Margin | $0.5 |
| Operating Margin | -947.2 |
| Profit as % of Revenues | -10.7% |
| Profit as % of Assets | -160.5% |
| Profit as % of Stockholder Equity | -261.3% |
Management Effectiveness
| Return on Equity | -261.3% |
| Return on Assets | -187.6% |
| Turnover Ratio | 17.2% |
| EBITA | $-5.1 |
Balance Sheet and Cash Flow Measures
| Total Assets | $2.7 |
| Total Liabilities | $0.8 |
| Operating Cash Flow | $-4 |
| Investing Cash Flow | $0 |
| Financing Cash Flow | $2.8 |
